Evidence map›Paper›PMID 39108617›Full record

ArticleGynecologic oncology reports2024

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer.

Michelle Greenman, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Alessandro D Santin

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06028932 (A Phase II Evaluation of Sacituzumab Govitecan), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06028932 phase2active not recruitingnot on this map

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Recurrent or Persistent Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

TypeinterventionalSponsorYale UniversityRan2024 to 2027Enrolled20ConditionsOvarian CarcinomaArmsSacituzumab govitecan
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michelle GreenmanDepartment of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT 06520, USA.
Stefania BelloneDepartment of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT 06520, USA.
Cem DemirkiranDepartment of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT 06520, USA.
Tobias Max Philipp HartwichDepartment of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT 06520, USA.
Alessandro D SantinDepartment of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT 06520, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Integrated genomic analysis of racial disparities in endometrial cancerU01CA176067 · NCI · YALE UNIVERSITY · PI SANTIN, ALESSANDRO D · 2014 to 2018
$1.7M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NCI NIH HHS U01 CA176067
6 · The paper itself

Abstract

Background: Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge. Novel treatment options for recurrent disease are an unmet need. Case: A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacituzumab govitecan after multiple failed lines of chemotherapy and targeted treatment. Following sacituzumab govitecan treatment she experienced a confirmed partial response as well as a return of CA-125 to baseline. Having now completed 8 cycles (ie, over 6 months of treatment), her disease continues to demonstrate a response to sacituzumab govitecan treatment. The ADC has been well tolerated at a dose of 10 mg/kg with no dose-limiting toxicity or need for dose reductions. Conclusion: Sacituzumab govitecan may represent a treatment option for platinum-resistant/recurrent HGSOC that have previously failed prior lines of chemotherapy. Clinical trials with sacituzumab govitecan in platinum-resistant ovarian cancer patients are currently ongoing (https://classic.clinicaltrials.gov/ct2/show/NCT06028932).

Indexed as

Antibody-drug conjugateHigh grade serous ovarian cancerSacituzumab govitecanTROP2

Identifiers

PMID39108617
PMCPMC11300917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.